Notably, NPC patients with the high level of both EphA2 and USP5 proteins had higher radioresistance, and poorer DFS and OS relative to the patients with the high level of one protein alone, indicating that a combination of USP5 and EphA2 could serve as an important marker for predicting NPC patient prognosis, and guiding personalized NPC radiotherapy. The gene discussed is EPHA2; the disease is nasopharyngeal carcinoma.